2 results about "Agkistrodon halys" patented technology

This invention pertains to the field of *Snakehead sinensis*, specifically relating to its characteristic polypeptides and their applications. Specifically, it covers the characteristic polypeptides of *Snakehead sinensis*, a mass spectrometry-based method for authenticity identification, and the application of these characteristic polypeptides in the preparation of drugs for treating rheumatoid arthritis. This invention provides a characteristic polypeptide, QDVDNASLVR, which is found only in *Snakehead sinensis* and can be stably detected. Its amino acid sequence is not reported in the literature, making it a novel polypeptide. An LC-MRM-MS method for authenticity identification based on this characteristic polypeptide is established, achieving accurate differentiation from *Snakehead rubrum* and *Agkistrodon halys*, with a 100% authenticity identification rate. This invention also provides a characteristic polypeptide, SFLGVPFAK, with anti-rheumatoid arthritis activity. Its amino acid sequence is not reported in the literature, making it a novel polypeptide. Its target and pathway can be predicted, or it can be applied to the modification of anti-rheumatoid arthritis active polypeptides.

The invention discloses a traditional Chinese medicine composition for treating scleroderma, which is prepared from the following traditional Chinese medicines in parts by weight: 60-100 parts of agkistrodon halys, 60-100 parts of cobra and 30-50 parts of dragon's blood. In the formula, the agkistrodon halys and the cobra have the effects of dispelling wind, dredging collaterals and resisting rheumatism, the dragon's blood has the effects of removing blood stasis and relieving pain, the formula conforms to the treatment principle of scleroderma for promoting blood circulation, removing blood stasis, dispelling wind and dredging collaterals, and research in recent years shows that the snake medicine still has the effect of regulating the immune function. Clinical experiment research shows that the treatment effect of the Soukang capsule taken by a scleroderma patient is compared with the treatment effect of a patient taking penicillamine in the same period, and the effectiveness and the safety of the Soukang capsule in treating systemic scleroderma are proved, so that the medicine disclosed by the invention has a remarkable effect of treating the scleroderma and has a good application value.